BEAM vs. SANA, NVAX, ADMA, DNA, FUSN, CGON, KYMR, INBX, APGE, and RXRX
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Sana Biotechnology (SANA), Novavax (NVAX), ADMA Biologics (ADMA), Ginkgo Bioworks (DNA), Fusion Pharmaceuticals (FUSN), CG Oncology (CGON), Kymera Therapeutics (KYMR), Inhibrx (INBX), Apogee Therapeutics (APGE), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry.
Sana Biotechnology (NASDAQ:SANA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 34.9% of Sana Biotechnology shares are owned by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sana Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.
Beam Therapeutics received 29 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 51.25% of users gave Beam Therapeutics an outperform vote while only 50.00% of users gave Sana Biotechnology an outperform vote.
Sana Biotechnology currently has a consensus price target of $11.67, suggesting a potential upside of 33.64%. Beam Therapeutics has a consensus price target of $40.18, suggesting a potential upside of 63.21%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Sana Biotechnology.
Sana Biotechnology has a net margin of 0.00% compared to Sana Biotechnology's net margin of -37.33%. Sana Biotechnology's return on equity of -15.46% beat Beam Therapeutics' return on equity.
In the previous week, Beam Therapeutics had 8 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Beam Therapeutics and 4 mentions for Sana Biotechnology. Beam Therapeutics' average media sentiment score of 0.46 beat Sana Biotechnology's score of 0.31 indicating that Sana Biotechnology is being referred to more favorably in the media.
Beam Therapeutics has higher revenue and earnings than Sana Biotechnology. Beam Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Beam Therapeutics beats Sana Biotechnology on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
